Neurocrine Biosciences has penned a deal with China’s TransThera Sciences potentially worth more than $880 million in biobucks for inhibitors aimed at a red-hot inflammation target. San Diego-based ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback